Suppr超能文献

相似文献

1
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.
Cell. 2016 Feb 11;164(4):770-9. doi: 10.1016/j.cell.2016.01.011. Epub 2016 Jan 28.
2
TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity.
Mol Ther. 2024 Nov 6;32(11):3915-3931. doi: 10.1016/j.ymthe.2024.08.018. Epub 2024 Aug 21.
3
Fully human antibody V domains to generate mono and bispecific CAR to target solid tumors.
J Immunother Cancer. 2021 Apr;9(4). doi: 10.1136/jitc-2020-002173.
5
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.
Cancer Discov. 2016 Feb;6(2):133-46. doi: 10.1158/2159-8290.CD-15-0583. Epub 2015 Oct 26.
6
PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
Hum Immunol. 2021 Feb;82(2):130-138. doi: 10.1016/j.humimm.2020.12.002. Epub 2020 Dec 16.
7
10

引用本文的文献

1
GD2T cells as a platform for single-dose and long-term delivery of biologics.
Nat Commun. 2025 Aug 29;16(1):8088. doi: 10.1038/s41467-025-63427-w.
2
CAR-T cell therapy for cancer: current challenges and future directions.
Signal Transduct Target Ther. 2025 Jul 4;10(1):210. doi: 10.1038/s41392-025-02269-w.
3
Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy.
Exp Hematol Oncol. 2025 Jul 2;14(1):92. doi: 10.1186/s40164-025-00683-y.
4
Cell-Based Therapies for Solid Tumors: Challenges and Advances.
Int J Mol Sci. 2025 Jun 9;26(12):5524. doi: 10.3390/ijms26125524.
5
Emerging frontiers in adoptive cell therapies: innovations, challenges, and future perspectives.
Med Oncol. 2025 Jun 15;42(7):261. doi: 10.1007/s12032-025-02808-z.
8
Editorial: Immune therapies in neurological disorders.
Front Neurosci. 2025 May 12;19:1615808. doi: 10.3389/fnins.2025.1615808. eCollection 2025.
9
CAR-T Cell Therapy: Managing Side Effects and Overcoming Challenges.
Adv Biomed Res. 2025 Apr 30;14:38. doi: 10.4103/abr.abr_531_23. eCollection 2025.

本文引用的文献

1
A robust pipeline for rapid production of versatile nanobody repertoires.
Nat Methods. 2014 Dec;11(12):1253-60. doi: 10.1038/nmeth.3170. Epub 2014 Nov 2.
2
Synthetic biology in mammalian cells: next generation research tools and therapeutics.
Nat Rev Mol Cell Biol. 2014 Feb;15(2):95-107. doi: 10.1038/nrm3738. Epub 2014 Jan 17.
3
Toxicity management for patients receiving novel T-cell engaging therapies.
Curr Opin Pediatr. 2014 Feb;26(1):43-9. doi: 10.1097/MOP.0000000000000043.
4
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses.
Sci Transl Med. 2013 Dec 11;5(215):215ra172. doi: 10.1126/scitranslmed.3006597.
5
Design and development of therapies using chimeric antigen receptor-expressing T cells.
Immunol Rev. 2014 Jan;257(1):107-26. doi: 10.1111/imr.12131.
6
Chimeric antigen receptor therapy for cancer.
Annu Rev Med. 2014;65:333-47. doi: 10.1146/annurev-med-060512-150254. Epub 2013 Nov 20.
7
Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
Mol Ther. 2013 Aug;21(8):1611-20. doi: 10.1038/mt.2013.110. Epub 2013 Jun 4.
8
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25.
10
Molecular mechanisms of T cell co-stimulation and co-inhibition.
Nat Rev Immunol. 2013 Apr;13(4):227-42. doi: 10.1038/nri3405. Epub 2013 Mar 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验